The company genetically engineers T cell therapies to specifically target and kill malignant cells in solid tumors. Their pipeline includes TCR T cell therapies and epigenetic drugs for the treatment of melanoma and head-and-neck carcinoma. Pan-Cancer T's innovative approach is based on 20 years of pioneering research in adoptive T-cell therapies, and they are dedicated to discovering breakthrough treatments for solid tumors.